Skip to main content
. Author manuscript; available in PMC: 2014 May 29.
Published in final edited form as: Breast Cancer Res Treat. 2011 Apr 9;131(3):849–858. doi: 10.1007/s10549-011-1500-8

Table 1.

Clinical data of Cleveland Clinic patients who received neoadjuvant chemotherapy with incomplete pathologic response.

Patient Age Tumor Type Pre-treatment
clinical T and
N
ER (% cells
immunoreactive)
PR (% cells
immunoreactive)
HER2
amplification
(HER2/CEP 17
ratio)
Pathologic
grade
Post-treatment
pathologic T and
N
Residual Cancer Burden Class
1 41 Ductal T3 N1 0.9 0.7 absent (1.3) 2 pT2 pN1 RCB-III
2 56 Lobular T3 N1 0.8 0.05 absent (1.3) 3 pT2 pN1 RCB-III
3 61 Ductal T2 N1 0.9 0.9 absent (1.4) 3 pT1 pN1 RCB-III
4 68 Lobular T2 N0 0.7 0.7 absent (1.0) 1 pT2 pN1 RCB-II
5 65 Ductal T2 N1 0.9 0.7 absent (1.4) 2 pT2 pN1 RCB-III
6 59 Ductal T3 N2 − (<5%) − (<5%) absent (1.0) 3 pT3 pN3 RCB-III
7 44 Ductal T3 N1 0.7 − (<5%) absent (1.3) 1 pT1 pN1 RCB-II
8 35 Ductal T2 N0 0.8 − (<5%) absent (1.8) 2 pT2 pN1 RCB-III